Aclaris Therapeutics, Inc. (ACRS) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $3.92. It has a SharesGrow Score of 55/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is ACRS = $10 (+155.1% upside).
Valuation: ACRS trades at a trailing Price-to-Earnings (P/E) of -7.4 (S&P 500 average ~25).
Financials: revenue is $8M, -31.1%/yr average growth. Net income is $65M (loss), growing at +0.6%/yr. Net profit margin is -829.6% (negative). Gross margin is 73.3% (+13.5 pp trend).
Balance sheet: total debt is $2M against $103M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 5.28 (strong liquidity). Debt-to-assets is 1.3%. Total assets: $160M.
Analyst outlook: 13 / 16 analysts rate ACRS as buy (81%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 30/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 50/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).
